RPL17 and melanoma: In murine melanoma models driven by BRAFV600E, anti-CSF1 inhibitors alone displayed modest efficacy, yet dual blockade of anti-CSF1 and anti-PD-1 regressed 100% of tumors by 17 days, with 90% survival after 90 days (123).